Circular Genomics is a biotechnology company pioneering the use of “circular RNAs” (circRNAs) as powerful, brain-derived biomarkers to revolutionize diagnosis and treatment in neurology and psychiatry. Their flagship test, MindLight™, aims to predict whether a patient with depression will respond to SSRI antidepressants, potentially reducing the long delays and trial-and-error common in psychiatric care. Meanwhile, their broader circRNA platform is being developed to deliver blood-based assays for diseases like Alzheimer’s disease, Parkinson’s disease and other neurological or psychiatric disorders, offering a non-invasive, molecular readout of brain health. By tapping into circRNAs—stable, brain-enriched RNA molecules detectable in blood—Circular Genomics aims to give clinicians a real-time, biologically detailed view of disease risk, progression, and treatment response, enabling more precise and personalized care for patients and families.